Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts - Wikidata - wikimedia - TriplyDB

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts

http://www.wikidata.org/entity/Q33216649

about

Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma Extracellularly activatable nanocarriers for drug delivery to tumors.Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids.Bromelain surface modification increases the diffusion of silica nanoparticles in the tumor extracellular matrix Changing the pathophysiology of solid tumours: the potential of TNF and other vasoactive agents.Kinetic analysis of hyaluronidase activity using a bioactive MRI contrast agent Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.Improving the distribution of Doxil® in the tumor matrix by depletion of tumor hyaluronan Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors.Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab Cancer drug delivery: considerations in the rational design of nanosized bioconjugates.Intratumoral drug delivery with nanoparticulate carriers.Hyaluronidase and collagenase increase the transfection efficiency of gene electrotransfer in various murine tumors.Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models Challenges to effective cancer nanotheranostics Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.Surface-active liposomes for targeted cancer therapy.Increased nanoparticle penetration in collagenase-treated multicellular spheroids Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor.Radionuclide carriers for targeting of cancer.Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing.Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model.Therapeutic targeting of hyaluronan in the tumor stroma.Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors.Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy.High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model.Cell membrane-derived nanomaterials for biomedical applications.Hyaluronan degrading silica nanoparticles for skin cancer therapy.Nanoformulations for combination or cascade anticancer therapy.

P2860

Q24614856-12E35DED-CEED-4F2C-B6A2-3DCCDE88A409 Q26799981-024559DF-8BC6-4A11-9B4E-83C0C0EAF00F Q26828930-89535AB0-C2C8-4AD8-8825-A88E9131E9C7 Q26999332-067F2799-3A8C-4EEE-9980-7ED4BD3D4F55 Q27002209-3E2A0AD8-2DBE-4679-BC2D-1DBD21A6FA85 Q27306235-A33F6EA2-0F9D-44A9-97EF-B2C09A1E227D Q28540889-E1D9E038-3343-4A0A-B419-5AF5A05480D2 Q29616287-87AB0FDA-9976-498A-AA60-F34EEC81BAF6 Q30401826-6B84F98F-D839-4221-9CA5-30101AC893AE Q30472417-B434B40C-A564-4817-92E0-36BC11D972C0 Q30596466-B6D7C30A-9EA0-44BB-9D77-9275F033D6B5 Q33245795-C81AC52E-81B7-430D-A1F4-618CFAD79B8C Q33671621-2F15E218-436E-48EA-A22B-1E8F0A60BFB7 Q34030709-728D87D7-ADC0-452E-A541-9428F587693F Q34145464-BFF9543C-C9FD-4F19-94C2-611377367CBD Q34366927-AE9E5CCE-2DE9-4BF4-80D3-13015301BB2E Q34621713-661DA196-B5BE-4214-AFC6-D5C03DEAAEE0 Q34764424-4BC6964D-1F0C-4202-8838-7854D994D399 Q35091415-F8FC7CF3-1B53-42CB-86A4-D202CA406AE6 Q35678411-5ED1968C-E1F1-4994-839B-CCE578DC59CD Q36043818-24A564EB-F4F6-41AA-98E4-CEF18AFF3B05 Q36334121-D7B47051-644D-4D5D-B1CA-295905D2F556 Q36417350-159C6F56-58C0-482E-8645-D31400DF30C0 Q36497582-19079BC6-BED8-404A-BE63-BDCC61C54BFA Q36791673-C760AB25-4FFB-487D-81DA-27DC71BF6612 Q36848111-94492217-6C17-46BD-A8D7-F5CDC1A87CE3 Q36988355-B1261E55-86B0-4C66-B0E4-CC062A09C178 Q37171112-AAF9FD6E-4F1D-4C37-88F4-D9FADD41D777 Q37188974-803D006D-76B1-46F5-BCE6-C0D3475F553A Q37237705-3AC55138-EEAB-4C4D-9C8C-CEBD5DD9D4D2 Q37381491-C6987FEC-FB6C-499D-B76D-7851ACAFFBDB Q37628989-4E3A4FE3-51A7-4979-B7E1-FF47C8268CBC Q38161392-B73041B6-FDBE-420E-A07E-EE3AB2ED996E Q38567353-E47B63E0-FC9B-46B4-A910-1BA46DFDB2E9 Q38676164-512826DD-1C4C-41A6-8903-037CB0628B7C Q38776676-1B6A94F2-A3B8-4D1C-BBF6-0D3BD99EBD33 Q38824126-55D76B64-1CA7-4BA4-96D0-BCA91FB55C68 Q39178313-BF0AA330-3066-4E46-87D6-FF4B1F0865C3 Q39362821-B8AF6B46-D369-4F43-97E0-AE91CC34C472 Q39380111-F96F42BD-D507-4752-BB14-E2E08EAB380A

P2860

Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts

http://www.wikidata.org/entity/Q33216649

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@ast

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@en

type

label

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@ast

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@en

prefLabel

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@ast

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@en

P1433

Q33216649-1290662A-8009-413D-9572-7F98D4F5D7CB

P1476

Q33216649-3F32AD0C-7A33-4563-ACCD-D9F5B453B9EC

P2093

Q33216649-9240A3A1-A955-4553-9F4C-605F325C4335

Q33216649-B7D15534-40F8-4741-B4D9-76896D0840C2

Q33216649-B9C0F83A-8AF2-4C99-83ED-42C381D7CF6C

Q33216649-B9DE24FC-947F-4FA7-8370-0503A8723977

P2860

Q33216649-05E8DC91-6EB2-4806-9A0E-EB2486BCA5A3

Q33216649-07FADC2A-5176-4EAC-9190-CD78E90451D2

Q33216649-0856658A-E814-4E62-A6E6-C8C49EB0C74F

Q33216649-2403404B-BA69-48D9-8F94-A2009C6566AE

Q33216649-257F52A5-E87D-41F3-BBE7-53671144EF5C

Q33216649-3A93B62C-341E-4C63-8C0E-B63FDAB9F2FF

Q33216649-3C6593FD-A6D9-4EB7-88C6-B2DE1E8A8775

Q33216649-3F35C5E5-DF4D-4F8A-8233-0DB618B9F46E

Q33216649-424B400B-A7B7-4091-8B2E-755E9E9F2FA6

Q33216649-462984A0-E04F-48D2-ABCF-0FF096FDC480

P2888

Q33216649-DB6118EC-97CC-4D5A-BD09-F0B3228E18F7

P304

Q33216649-4C566E24-5CDE-4D2B-841A-FA30DC6E4ACF

P31

Q33216649-506F2C30-A605-4554-BB5B-F69F759906A4

P356

Q33216649-0AB019D9-C68E-462F-A828-206173C2ED58

P407

Q33216649-8F1C896A-03A9-46A6-8350-5BB0B581C7D5

P433

Q33216649-3BAB271F-9194-4B76-BF40-F7D4F0C57CBD

P478

Q33216649-121A34AB-D747-4FC3-A8D6-C7EC4767CA72

P50

Q33216649-10540DB0-FB57-4089-A6DD-C63F4ADFC7B7

P577

Q33216649-EFBBA26E-9DA0-4BE6-B0F1-DCB632C7A1E1

P5875

Q33216649-49A9DB79-E686-45F0-A3B2-47DF1FF8CBA4

P6179

Q33216649-91A3CBA2-96EB-4237-A23F-B26BF77DBC7D

P698

Q33216649-F6756B5E-959D-4271-BF11-930474609F15

P921

Q33216649-44F5D3E5-66D8-482F-857E-AD999E6CEABD

P932

Q33216649-5C45CC4D-9245-4FC7-81E0-778B2BC0F749

P356

P1433

British Journal of Cancer

P1476

Hyaluronidase induces a transc ...... human osteosarcoma xenografts

@en

P2093

C de Lange Davies

http://www.w3.org/2001/XMLSchema#string

I Tufto

http://www.w3.org/2001/XMLSchema#string

L Eikenes

http://www.w3.org/2001/XMLSchema#string

M Tari

http://www.w3.org/2001/XMLSchema#string

P2860

Permeation of the luminal capillary glycocalyx is determined by hyaluronan.

Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase.

Systemic therapy emergencies.

Current treatment of osteosarcoma.

Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors.

Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma

Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells.

Radiation improves the distribution and uptake of liposomal doxorubicin (caelyx) in human osteosarcoma xenografts.

Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death.

Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.

P2888

P304

81-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6602626

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Øyvind Sverre Bruland

P577

2005-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7799015

http://www.w3.org/2001/XMLSchema#string

P6179

1034660204

http://www.w3.org/2001/XMLSchema#string

P698

15942637

http://www.w3.org/2001/XMLSchema#string

P921

P932

2361478

http://www.w3.org/2001/XMLSchema#string